Cyteir Therapeutics Completes Initial Public Offering to Support Cancer Therapy Programs

By David Evans Shaw

June 26, 2021.   As a co-founder of the company, I’m pleased to share that Cyteir Therapeutics has completed an initial public offering to support our discovery and development programs for next generation cancer therapies.  This offering consisted of 7.2 million shares of stock at $18 per share.  

Our news release for the IPO can be found HERE

It’s been an honor for me to play a founding role in the creation and development of this innovative organization focused on a new generation of precision oncology medicines.   The technology to launch Cyteir came from The Jackson Laboratory, a leading mammalian genetics institute where I am chair emeritus..  Since a Series A financing in 2015 the company has made very significant progress in advancing a pipeline of drug candidates that selectively target key cancer vulnerabilities.  We announced our first presentation data from a first-in-human Phase 1/2 study earlier this month, which can be read HERE

Congratulations to the Cyteir team for their remarkable accomplishments.  More information about the company can be found on our website